Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:DMRA NASDAQ:IMTX NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$22.42+37.9%$15.33$3.39▼$23.71$587.25M0.78774,942 shs12.77 million shsDMRADamora Therapeutics, Inc. Common Stock$26.05+4.7%$26.53$2.45▼$38.33$1.57B1.5232,576 shs18,201 shsIMTXImmatics$11.27+2.9%$10.31$3.94▼$12.41$1.51B1.31426,706 shs65,587 shsNTLAIntellia Therapeutics$13.73+3.2%$13.63$6.83▼$28.25$1.65B1.935.29 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+18.60%+26.44%-8.45%+13.15%+223.90%DMRADamora Therapeutics, Inc. Common Stock-1.93%+2.64%-0.88%+4.58%+718.09%IMTXImmatics+1.48%-5.52%+5.80%+17.24%+114.71%NTLAIntellia Therapeutics+0.38%+0.83%+1.37%+7.69%+57.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$22.42+37.9%$15.33$3.39▼$23.71$587.25M0.78774,942 shs12.77 million shsDMRADamora Therapeutics, Inc. Common Stock$26.05+4.7%$26.53$2.45▼$38.33$1.57B1.5232,576 shs18,201 shsIMTXImmatics$11.27+2.9%$10.31$3.94▼$12.41$1.51B1.31426,706 shs65,587 shsNTLAIntellia Therapeutics$13.73+3.2%$13.63$6.83▼$28.25$1.65B1.935.29 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+18.60%+26.44%-8.45%+13.15%+223.90%DMRADamora Therapeutics, Inc. Common Stock-1.93%+2.64%-0.88%+4.58%+718.09%IMTXImmatics+1.48%-5.52%+5.80%+17.24%+114.71%NTLAIntellia Therapeutics+0.38%+0.83%+1.37%+7.69%+57.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.91Moderate Buy$48.14114.78% UpsideDMRADamora Therapeutics, Inc. Common Stock 2.88Moderate Buy$43.4066.60% UpsideIMTXImmatics 2.67Moderate Buy$19.0068.60% UpsideNTLAIntellia Therapeutics 2.35Hold$20.0946.29% UpsideCurrent Analyst Ratings BreakdownLatest AVTX, NTLA, DMRA, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026AVTXAvalo Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$52.00 ➝ $62.005/6/2026AVTXAvalo Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $40.005/6/2026AVTXAvalo Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $58.004/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/28/2026IMTXImmatics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/28/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $58.004/28/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$28.00 ➝ $30.004/27/2026NTLAIntellia Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.004/27/2026NTLAIntellia Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$11.00 ➝ $15.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$60K9,978.41N/AN/A$4.49 per share4.99DMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AIMTXImmatics$54.60M27.67N/AN/A$4.09 per share2.76NTLAIntellia Therapeutics$67.67M24.44N/AN/A$5.80 per share2.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$78.26M-$5.73N/AN/AN/AN/A-77.91%-61.78%5/11/2026 (Estimated)DMRADamora Therapeutics, Inc. Common Stock-$209.84M-$12.10N/AN/AN/AN/A-147.05%-279.49%N/AIMTXImmatics-$222.26M-$1.84N/AN/AN/A-411.90%-41.81%-34.72%5/12/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.83N/AN/AN/A-609.85%-56.81%-45.34%5/14/2026 (Estimated)Latest AVTX, NTLA, DMRA, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026NTLAIntellia Therapeutics-$0.92N/AN/AN/A$13.81 millionN/A5/12/2026Q1 2026IMTXImmatics-$0.42N/AN/AN/A$9.79 millionN/A5/11/2026Q1 2026AVTXAvalo Therapeutics-$1.00N/AN/AN/A$0.05 millionN/A3/23/2026Q4 2025AVTXAvalo Therapeutics-$1.54-$0.37+$1.17-$0.37($0.21) million$0.06 million3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 million2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ADMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A8.148.14DMRADamora Therapeutics, Inc. Common StockN/A12.9812.98IMTXImmaticsN/A11.7211.72NTLAIntellia TherapeuticsN/A5.085.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%DMRADamora Therapeutics, Inc. Common Stock14.20%IMTXImmatics64.41%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics4.46%DMRADamora Therapeutics, Inc. Common Stock10.46%IMTXImmaticsN/ANTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4026.71 million25.52 millionNot OptionableDMRADamora Therapeutics, Inc. Common Stock4060.30 million54.00 millionNo DataIMTXImmatics260134.07 millionN/AOptionableNTLAIntellia Therapeutics600120.46 million114.47 millionOptionableAVTX, NTLA, DMRA, and IMTX HeadlinesRecent News About These CompaniesIntellia Therapeutics to Participate in Upcoming Investor ConferencesMay 5 at 7:30 AM | globenewswire.comNTLA Q2 EPS Increased by Brookline Capital MarketsMay 4 at 1:01 AM | marketbeat.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comIntellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity Raise - Has The Bull Case Changed?April 30, 2026 | finance.yahoo.comIntellia Therapeutics stock tumbles on dilutive offeringApril 30, 2026 | au.investing.comIntellia Therapeutics prices $180M stock offering at discountApril 30, 2026 | msn.comWhy Intellia Therapeutics, Inc.’s (NTLA) Stock Is Down 6.01%April 30, 2026 | aaii.comAIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?April 29, 2026 | marketbeat.comIntellia Therapeutics Announces Pricing of Public Offering of Common StockApril 29, 2026 | globenewswire.comCathie Wood just made a massive bet on these two top AI stocksApril 29, 2026 | finbold.comFIntellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $58.00 at Canaccord Genuity GroupApril 28, 2026 | marketbeat.comNTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLAApril 28, 2026 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6% After Analyst UpgradeApril 28, 2026 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at Citizens JmpApril 28, 2026 | marketbeat.comIntellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA FilingApril 27, 2026 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema TranscriptApril 27, 2026 | seekingalpha.comIntellia Announces Proposed Public Offering of Common StockApril 27, 2026 | globenewswire.comIntellia Stock Jumps 25%. A Key Trial Is Driving the RallyApril 27, 2026 | finance.yahoo.comIntellia successfully edited genes inside the body. Why shares aren't flyingApril 27, 2026 | msn.comChardan Capital Forecasts Strong Price Appreciation for Intellia Therapeutics (NASDAQ:NTLA) StockApril 27, 2026 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema - SlideshowApril 27, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026AVTX, NTLA, DMRA, and IMTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$22.42 +6.16 (+37.85%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA$26.05 +1.18 (+4.74%) As of 10:33 AM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Immatics NASDAQ:IMTX$11.27 +0.32 (+2.91%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Intellia Therapeutics NASDAQ:NTLA$13.73 +0.42 (+3.16%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
